[WS(P)29] Cell therapy, vaccine, and new therapeutic modality

[WS29-08-O/P] Breast cancer specific antigen recognition by TIL-derived MR1-restricted TCRs

^○Abdul Hayee¹, Eiji Kobayashi¹, Hiroshi Hamana², Chihiro Motozono³, Satoshi Yamaguchi¹, Ha Thi Viet My¹, Tatsuhiko Ozawa¹, Hiroyuki Kishi¹ (1.Department of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan, 2.Shinobi Therapeutics Co., Ltd., Kyoto, Japan, 3.Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan)

キーワード：

Breast cancer、Tumor infiltrating lymphocytes、MR1、T cell receptors

閲覧にはパスワードが必要です

ログイン

または